Perspective Article - (2025) Volume 14, Issue 1
Received: 02-Mar-2025, Manuscript No. jms-25-164575;
Editor assigned: 04-Mar-2025, Pre QC No. P-164575;
Reviewed: 17-Mar-2025, QC No. Q-164575;
Revised: 24-Mar-2025, Manuscript No. R-164575;
Published:
31-Mar-2025
, DOI: 10.37421/2167-0943.2025.14.396
Citation: Raben, Yutao."Skin Microbiota: A Key Mediator between Metabolic Disorders and Cutaneous Health and Disease." J Metabolic Synd 14 (2025): 396.
Copyright: © 2025 Raben Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The composition of the skin microbiota varies depending on anatomical location, environmental factors, and host genetics. Sebaceous areas, moist regions, and dry skin surfaces each harbor distinct microbial communities, with dominant bacterial genera including Staphylococcus, Cutibacterium, and Corynebacterium. In individuals with metabolic disorders, systemic changes such as increased inflammation, altered lipid metabolism, and hyperglycemia can shift microbial diversity, favoring the proliferation of pathogenic species and reducing beneficial commensals. For example, in obesity, excess sebum production and changes in skin pH create an environment conducive to Staphylococcus aureus colonization, which is implicated in inflammatory skin conditions such as atopic dermatitis. Similarly, insulin resistance and hyperglycemia in diabetes can promote microbial overgrowth and impair skin barrier function, leading to increased susceptibility to infections and delayed wound healing [2].
Microbial dysbiosis also plays a critical role in chronic inflammatory skin diseases. In psoriasis, alterations in skin microbiota composition, particularly a decrease in Cutibacterium species and an increase in Streptococcus and Corynebacterium, contribute to immune activation and cytokine release. Atopic dermatitis is associated with reduced microbial diversity and an overrepresentation of Staphylococcus aureus, which exacerbates skin inflammation by producing virulence factors that disrupt the epidermal barrier. Acne, another common skin condition, is influenced by shifts in Cutibacterium acnes strains, with metabolic disorders potentially modulating lipid composition and bacterial interactions. Furthermore, metabolic endotoxemia characterized by Increased Circulating Lipopolysaccharides (LPS) from gut microbiota dysbiosis has been proposed as a link between systemic inflammation and cutaneous manifestations, highlighting the interconnectedness of metabolic and dermatological health [3].
The impact of metabolic disorders on skin microbiota is bidirectional, as dysbiosis can also influence systemic metabolic health. Skin microbiota-derived metabolites, such as short-chain fatty acids and antimicrobial peptides, have been shown to modulate immune responses, insulin sensitivity, and lipid metabolism. Moreover, alterations in the skin barrier and local inflammation may contribute to systemic inflammatory load, aggravating metabolic conditions. The gut-skin axis further underscores this connection, with gut microbiota-derived metabolites influencing skin microbial composition and immune responses. Recent studies suggest that probiotic and prebiotic interventions targeting both gut and skin microbiota may offer therapeutic potential in managing metabolic disorders and associated skin conditions [4].
Despite growing evidence supporting the interplay between metabolic health and skin microbiota, several challenges remain in elucidating the precise mechanisms driving these interactions. Variability in individual microbiome composition, genetic predisposition, lifestyle factors, and environmental exposures complicate the establishment of definitive causal relationships. Additionally, while emerging microbiome-targeted therapies including topical probiotics, bacteriophage therapy, and microbiome-friendly skincare products show promise in restoring microbial balance, their long-term efficacy and safety require further investigation. Future research should focus on integrating multi-omics approaches, including metagenomics, transcriptomics, and metabolomics, to comprehensively map the interactions between skin microbiota, metabolic disorders, and immune function. Large-scale clinical trials are also needed to assess the effectiveness of microbiome-based interventions in improving both metabolic and dermatological health outcomes [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Journal of Metabolic Syndrome received 48 citations as per Google Scholar report